CEO scouts top E&W Coast scientific talent to secure Merck & Co.'s future

‘Don’t underestimate Merck's vaccine business,’ says CEO

By Dan Stanton contact

- Last updated on GMT

Merck & Co.'s top-selling vaccine is its HPV vaccination Gardasil/Gardasil 9. Image: By Jan Christian @ www.ambrotosphotography.com CC BY-SA 2.0 (http://creativecommons.org/licenses/by-sa/2.0), via Wikimedia Commons
Merck & Co.'s top-selling vaccine is its HPV vaccination Gardasil/Gardasil 9. Image: By Jan Christian @ www.ambrotosphotography.com CC BY-SA 2.0 (http://creativecommons.org/licenses/by-sa/2.0), via Wikimedia Commons

Related tags: Vaccine

CEO Ken Frazier has told investors investments and partnerships, such as collaboration with messenger RNA firm Moderna Therapeutics, have bolstered Merck & Co.’s vaccine division.

In 2016, Merck & Co. (known as MSD outside North America) reported worldwide sales of $4.7bn (€4.2bn) for its vaccines business.

This was down 8% year-on-year, and the sector’s contribution to the big pharma’s total revenues (12%) also dropped, but CEO Ken Frazier told investors at last week’s Sanford Bernstein Strategic Decision Conference he is “excited” by the pipeline and it remains a strong part of Merck’s business.

“I think if you look at how well Gardasil [Merck’s human papillomavirus vaccine] was doing now with that launch of Gardasil 9, if you look at the work that we are doing early on with Moderna in terms of the RNA platform that we’re able to use there, we have a PCV [pneumococcal conjugate vaccine] vaccine in the pipeline, I am very excited about that.”

Merck and Moderna have a collaboration and license agreement focused on the discovery and development of messenger RNA-based (mRNA-based) vaccines, and last year Merck paid the Cambridge, Massachusetts-based firm $200m upfront o advance Novel a personalised cancer vaccines with its best-selling biologic Keytruda (pembrolizumab).

“That’s the kind of transaction where I think we can create value for our shareholders, because our scientists see something that they believe they can employ in the context of vaccine development down the line,”​ Frazier said on Friday.

Attracting and recruiting top talent

Merck is one of just a handful of players which control the vaccine industry, the others being GSK, Sanofi, and Pfizer. Recently Sanofi Pasteur warned of a lack of skilled workers​ in the vaccine space jeopardising future opportunities.

But Frazier said his firm was looking ahead to the future through scouting scientific talent both for its vaccine and other divisions.

“We are starting at the very early stages to recruit the next generation of scientific talent in San Francisco and in Cambridge and on new discovery hubs and I have just visited San Francisco a couple of weeks ago,”​ he said.

“And when you walk around the halls there, you have really tremendously talented young scientists who are eager to make their career at a place like Merck. And I know that’s a little long range, but at the end of the day, the quality of a company like Merck really ultimately hinges on our ability to recruit and retain the top scientific talents.”

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Related suppliers

Follow us

Products

View more

Webinars